Multiple trials recently investigated the benefits of GIP/GLP-1 medications in mitigating acute and chronic cardiovascular stressors.6,9,10 For instance, both the LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide showed significant reductions in MACE in patients with T2DM and high cardiovascular risk. The gene discussed is GCG; the disease is type 2 diabetes mellitus.